What this pack is
FELDENE is the brand name in this record; piroxicam oral capsules is the generic name. Read both together with the dosage form (oral capsule).
PACK CHECK · MARKET FIRST
FELDENEGeneric namepiroxicam oral capsules
How this medicine works
The FDA label classifies piroxicam as an NSAID. For ordinary readers, the key point is that a shared mechanism does not create a shared regimen: prostaglandin pathways relate to pain and inflammation as well as gastrointestinal, kidney, platelet and pregnancy-related physiology, and a mechanism page cannot determine an individual amount or whether another medicine should be replaced.
Read source: United States ↗reviewed 2026-09-13More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- FELDENE
- Generic name
- piroxicam oral capsules
- Dosage-form class
- Oral capsules. The dated FDA document lists two labelled strengths, 10 mg and 20 mg; different medicines, NSAIDs or market packs cannot be self-substituted, combined or used to select a tablet count from milligram figures alone.
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PACKAGE-VISUAL STATUS
No exact FELDENE package image was individually verified; look-alike packs are not substituted
The reviewed FDA brand label and DailyMed Medication Guide support identity and safety reading, not an exact publicly verifiable market-pack image. The page therefore retains dosage-form and source text and withholds retail images, look-alike capsules and screenshots that could imply an exact package, availability or authenticity.
LABEL READING · NOT A PRESCRIPTION
FELDENE enlarged label: first exclude duplicate NSAIDs, then recognise bleeding, cardiovascular and serious skin warnings
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
Black stools, vomiting blood, chest pain, shortness of breath, one-sided weakness or speech difficulty, face or throat swelling, markedly reduced urine, rapid swelling, blistering or skin peeling are not situations for continued self-trial from a webpage and require timely local medical support. The site provides no individual dose, frequency, course, catch-up or switching plan.
- Do not self-combine, alternate or convert FELDENE with ibuprofen, naproxen, diclofenac, celecoxib, etoricoxib or aspirin merely because they are used for pain. The shared NSAID class instead signals a need to check duplication and risk first.
- Prior ulcer or gastrointestinal bleeding, medicines affecting haemostasis, SSRI/SNRI medicines, ACE inhibitors/ARBs, diuretics, lithium, methotrexate and other NSAIDs on the same list require review against the complete list and exact product; the site does not generate spacing or stopping instructions.
- The FDA Medication Guide warns that NSAIDs can cause serious cardiovascular and gastrointestinal adverse reactions. Older adults and people with cardiovascular disease, kidney disease, heart failure, dehydration or multiple medicines must not interpret a common pain medicine as permission to self-add it.
- A name match cannot confirm capsule strength, an exact pack, authenticity or individual suitability. Check the actual pack, source date, prescription and complete medicine list together.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkFDA · United States · Regulatory product record or label archive · 2026-09-13
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeFDA: FELDENE (piroxicam) 10 mg/20 mg U.S. oral-capsule prescribing information (NDA 018147; revised Apr 2021; dated historical document) ↗reviewed 2026-09-13
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about FELDENE (piroxicam oral capsules). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
FELDENE is the brand in this record and piroxicam oral capsules is the active-ingredient name. Check both with the dosage form (Oral capsules. The dated FDA document lists two labelled strengths, 10 mg and 20 mg; different medicines, NSAIDs or market packs cannot be self-substituted, combined or used to select a tablet count from milligram figures alone.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): FDA-approved NSAID Medication Guide for FELDENE (piroxicam) (Pfizer; revised Jan 2025) ↗Current regulatory record · reviewed 2026-09-13
- FDA: FELDENE (piroxicam) 10 mg/20 mg U.S. oral-capsule prescribing information (NDA 018147; revised Apr 2021; dated historical document) ↗reviewed 2026-09-13
HOW IT WORKS · NOT A TREATMENT PLAN
How piroxicam works: NSAID and prostaglandin-pathway risk reading
- The NSAID class cannot determine an individual's dose, frequency, course, catch-up or switching plan.
- Being in the same NSAID class does not permit co-use; first identify duplicate pain, cold and aspirin products on the medicine list.
- When warning signs occur, a mechanism explanation does not replace local medical support.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- FDA: FELDENE (piroxicam) 10 mg/20 mg U.S. oral-capsule prescribing information (NDA 018147; revised Apr 2021; dated historical document) ↗reviewed 2026-09-13
- DailyMed (NLM): FDA-approved NSAID Medication Guide for FELDENE (piroxicam) (Pfizer; revised Jan 2025) ↗Current regulatory record · reviewed 2026-09-13
- FDA Drugs@FDA: official lookup entry for FELDENE / piroxicam NDA 018147 ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
FELDENEpiroxicam oral capsules
This page links to public primary-source material for FELDENE. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the label
The dated FDA prescribing information lists Initial U.S. Approval: 1982; this only locates U.S. brand history.
FDA: FELDENE (piroxicam) 10 mg/20 mg U.S. oral-capsule prescribing information (NDA 018147; revised Apr 2021; dated historical document) ↗Dated FDA brand prescribing-information revision
The reviewed PDF filename and label text identify an April 2021 revision.
FDA: FELDENE (piroxicam) 10 mg/20 mg U.S. oral-capsule prescribing information (NDA 018147; revised Apr 2021; dated historical document) ↗DailyMed Medication Guide revision
The reviewed FDA-approved NSAID Medication Guide identifies Pfizer and a January 2025 revision.
DailyMed (NLM): FDA-approved NSAID Medication Guide for FELDENE (piroxicam) (Pfizer; revised Jan 2025) ↗
MARKET SCOPE
Market-record boundary
United States
Dated brand label and Medication Guide linkedThe documents locate historical regulatory information and do not establish current stock, purchase, authenticity or individual suitability.
Mainland China, EU, Japan and other markets
Current local record not yet establishedNo local approval, brand, supply, originator/generic relationship or interchangeability is inferred from a U.S. NDA, English brand or U.S. label.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Can FELDENE be used with ibuprofen or naproxen?
Do not self-combine them merely because all are used for pain. They are NSAIDs and may increase risk; have all prescriptions, OTC products and supplements reviewed by a pharmacist or clinician.
Can 10 mg and 20 mg be self-converted from the numbers?
No. Label strength is an exact-product identity field, not an individual tablet count, frequency, catch-up or course instruction.
How can I check a product when the page has no pack image?
This page does not use unverified look-alike images. Check the actual pack, generic name, dosage form, source date, prescription and local official lookup route; for authenticity or medicine-use concerns, contact a local licensed pharmacist or care team.
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.